Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
December 04 2019 - 8:30AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a
leader in the commercialization and development of prescription
ophthalmology treatments for the management of retinal diseases,
today announces that Rick Eiswirth, President and Chief Executive
Officer of Alimera, will be a featured presenter at the LD Micro
Main Event on Tuesday, December 10, 2019 at 12:40 PM Pacific Time
at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Mr. Eiswirth will provide an overview of the company’s business
model and growth strategy and will be available for one-on-one
meetings. In addition, his presentation will be webcast. To access
the webcast, please visit http://wsw.com/ldmicro17/alim at the time
of the presentation. The webcast will also be archived for 90 days
and may be subsequently accessed on the Company’s website. For
those interested in attending or for registered attendees who wish
to request meetings, please contact David Scher at
david@ldmicro.com or visit www.ldmicro.com for more
information.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals for the management of
retinal diseases. Alimera is presently focused on diseases
affecting the back of the eye, or retina, because these diseases
are not well treated with current therapies and will affect
millions of people in our aging populations. For more information,
please visit www.alimerasciences.com.
About
ILUVIEN®
The Company’s primary product is ILUVIEN (fluocinolone acetonide
intravitreal implant) 0.19 mg sustained release intravitreal
implant, injected into the back of the eye. With its CONTINUOUS
MICRODOSING™ technology, ILUVIEN is designed to release
sub-microgram levels of fluocinolone acetonide, a corticosteroid,
for 36 months, to reduce the recurrence of disease, enabling
patients to maintain vision longer with fewer injections. ILUVIEN
is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to
treat diabetic macular edema (DME) in patients who have been
previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure. In 17
European countries, ILUVIEN is indicated for the treatment of
vision impairment associated with chronic DME considered
insufficiently responsive to available therapies. In March 2019,
ILUVIEN received approval in the 17 countries under the Mutual
Recognition Procedure for prevention of relapse in recurrent
non-infectious uveitis affecting the posterior segment of the eye.
The 17 European countries include the U.K., Germany, France, Italy,
Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway,
Finland, Sweden, Poland, Czech Republic, the Netherlands, and
Luxembourg. The regulatory process is now in the national phase in
which the European member states have finalized or are expected to
finalize the label for the new indication to meet each country’s
local requirements. Timeline to this goal varies by each country,
and the non-infectious posterior uveitis indication for ILUVIEN was
launched in Germany and the U.K. in 3Q 2019. ILUVIEN is not
approved for treatment of uveitis in the United States.
For
press inquiries: |
For
investor inquiries: |
Jules Abraham |
Scott Gordon |
for Alimera Sciences |
for Alimera Sciences |
917-885-7378 |
scottg@coreir.com |
julesa@coreir.com |
|
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024